

Lucia Del Vecchio

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9221625/publications.pdf>

Version: 2024-02-01

14
papers

1,020
citations

1163117

8
h-index

1125743

13
g-index

14
all docs

14
docs citations

14
times ranked

1324
citing authors

#	ARTICLE	IF	CITATIONS
1	Kidney Disease: Improving Global Outcomes guidelines on anaemia management in chronic kidney disease: a European Renal Best Practice position statement. <i>Nephrology Dialysis Transplantation</i> , 2013, 28, 1346-1359.	0.7	628
2	Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised, placebo-controlled phase 2b trial. <i>Lancet, The</i> , 2017, 389, 2117-2127.	13.7	278
3	Mineralocorticoid receptor antagonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. <i>Nephrology Dialysis Transplantation</i> , 2023, 38, 10-25.	0.7	30
4	A Role for SGLT-2 Inhibitors in Treating Non-diabetic Chronic Kidney Disease. <i>Drugs</i> , 2021, 81, 1491-1511.	10.9	18
5	Types of erythropoiesis-stimulating agents and risk of end-stage kidney disease and death in patients with non-dialysis chronic kidney disease. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, 267-274.	0.7	13
6	Intravenous iron therapy and the cardiovascular system: risks and benefits. <i>CKJ: Clinical Kidney Journal</i> , 2021, 14, 1067-1076.	2.9	12
7	Rituximab Therapy for Adults with Nephrotic Syndromes: Standard Schedules or B Cell-Targeted Therapy?. <i>Journal of Clinical Medicine</i> , 2021, 10, 5847.	2.4	11
8	Impact of European medicines agency recommendations for hypersensitivity reactions on intravenous iron prescription in haemodialysis centres of the Lombardy region. <i>Journal of Nephrology</i> , 2016, 29, 673-681.	2.0	8
9	Safety and Efficacy of Eculizumab Therapy in Multiple Sclerosis: A Case Series. <i>Brain Sciences</i> , 2021, 11, 1341.	2.3	7
10	Is it the agent or the blood pressure level that matters for renal and vascular protection in chronic nephropathies?. <i>Kidney International</i> , 2005, 67, S15-S19.	5.2	6
11	The evolution of the therapeutic approach to membranous nephropathy. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, 768-773.	0.7	5
12	Ferric Carboxymatose in Non-Hemodialysis CKD Patients: A Longitudinal Cohort Study. <i>Journal of Clinical Medicine</i> , 2021, 10, 1322.	2.4	2
13	Nefecon (targeted-release formulation-budesonide) for the treatment of IgA nephropathy. <i>Future Rare Diseases</i> , 2021, 1, .	0.4	2
14	The treatment of membranous nephropathy: a journey in the search for evidence. <i>Journal of Nephrology</i> , 2022, , 1.	2.0	0